Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATRIX-RARE
2024-513779-42-02Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odronextamab, dabrafenib + trametinib, trametinib, vorasidenib, ivosidenib and 2 more in rare cancer, cancer, glioblastoma (GBM) and 2 more, sponsored by Oslo University Hospital. Primary endpoints: Disease control at 16 weeks, Grade 3 or higher and serious treatment-related adverse events and 1 more. Planned start Mar 2025; status: authorised.
02
Drugs
odronextamabdabrafenib + trametinibtrametinibvorasidenibivosidenib
03
Conditions
rare cancercancerglioblastoma (GBM)ovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2024-513779-42-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513779-42-02.